Amplia Therapeutics (INNMF) Stock Statistics & Valuation Metrics
Total Valuation
Amplia Therapeutics has a market cap or net worth of $30.32M. The enterprise value is $93.06M.
- Market Cap
- $30.32M
- Enterprise Value
- $93.06M
Share Statistics
Amplia Therapeutics has 513,312,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 513,312,000
- Owned by Insiders
- 3.47%
- Owned by Institutions
- ―
Financial Efficiency
Amplia Therapeutics’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.41%.
- Return on Equity (ROE)
- -0.20
- Return on Assets (ROA)
- -0.19
- Return on Invested Capital (ROIC)
- -20.41%
- Return on Capital Employed (ROCE)
- -0.33
- Revenue Per Employee
- 0
- Profits Per Employee
- -963.39K
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Amplia Therapeutics is -5.03. Amplia Therapeutics’s PEG ratio is -0.21.
- PE Ratio
- -5.03
- PS Ratio
- 0.00
- PB Ratio
- 1.09
- Price to FCF
- -4.92
- Price to Operating Cash Flow
- -4.93
- PEG Ratio
- -0.21
Income Statement
In the last 12 months, Amplia Therapeutics had revenue of 0 and earned -7.71M in profits. Earnings per share was -0.02.
- Revenue
- 0
- Gross Profit
- -92.14K
- Operating Income
- -13.18M
- Pretax Income
- -12.49M
- Net Income
- -7.71M
- EBITDA
- -13.09M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -8.73M and capital expenditures -33,306, giving a free cash flow of -8.77M billion.
- Operating Cash Flow
- -8.73M
- Free Cash Flow
- -8.77M
- Free Cash Flow per Share
- -0.02
Dividends & Yields
Amplia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -20.33%
- Earnings Yield
- -17.88%
Stock Price Statistics
- Beta
- -1.47
- 52-Week Price Change
- -39.33%
- 50-Day Moving Average
- 0.08
- 200-Day Moving Average
- 0.10
- Relative Strength Index (RSI)
- 39.59
- Average Volume (3m)
- 35.15K
Important Dates
Amplia Therapeutics upcoming earnings date is Nov 25, 2026, TBA (Not Confirmed).
- Last Earnings Date
- May 29, 2026
- Next Earnings Date
- Nov 25, 2026
- Ex-Dividend Date
- ―
Financial Position
Amplia Therapeutics as a current ratio of 19.78, with Debt / Equity ratio of 0.86%
- Current Ratio
- 19.78
- Quick Ratio
- 19.78
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.10
- Interest Coverage Ratio
- -758.70
Taxes
In the past 12 months, Amplia Therapeutics has paid -4.78M in taxes.
- Income Tax
- -4.78M
- Effective Tax Rate
- 0.38
Enterprise Valuation
Amplia Therapeutics EV to EBITDA ratio is -1.21, with an EV/FCF ratio of -1.78.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.21
- EV to Free Cash Flow
- -1.78
- EV to Operating Cash Flow
- -1.79
Balance Sheet
Amplia Therapeutics has $27.85M in cash and marketable securities with $341.11K in debt, giving a net cash position of $27.51M billion.
- Cash & Marketable Securities
- $27.85M
- Total Debt
- $341.11K
- Net Cash
- $27.51M
- Net Cash Per Share
- $0.05
- Tangible Book Value Per Share
- $0.06
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Amplia Therapeutics is $0.30, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $0.30
- Price Target Upside
- 447.49% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 20.29%
Scores
- Smart Score
- 5
- AI Score
- ―
